Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Public ClinicalTrials.gov record NCT07146022. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Study identification
- NCT ID
- NCT07146022
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 552 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 25, 2025 (Actual)
- Primary completion
- Jun 2027 (Estimated)
- Completion
- Jan 2028 (Estimated)
- Last update posted
- Aug 17, 2026
2025 – 2028
United States locations
- U.S. sites
- 71
- U.S. states
- 28
- U.S. cities
- 68
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 73 | Birmingham | Alabama | 35209 | — |
| Site 89 | Birmingham | Alabama | 35244 | — |
| Site 77 | Phoenix | Arizona | 85006 | — |
| Site 30 | Fort Smith | Arkansas | 72916 | — |
| Site 69 | Encino | California | 91436 | — |
| Site 2 | Fremont | California | 94538 | — |
| Site 64 | Manhattan Beach | California | 90266 | — |
| Site 93 | Northridge | California | 91324 | — |
| Site 66 | Santa Monica | California | 90404 | — |
| Site 34 | Sherman Oaks | California | 91403 | — |
| Site 94 | Thousand Oaks | California | 91320 | — |
| Site 21 | Vista | California | 92083 | — |
| Site 5 | Castle Rock | Colorado | 80109 | — |
| Site 24 | Greenwood Village | Colorado | 80111 | — |
| Site 17 | Aventura | Florida | 33180 | — |
| Site 71 | Boca Raton | Florida | 33486 | — |
| Site 86 | Coral Gables | Florida | 33134 | — |
| Site 62 | Coral Gables | Florida | 33146 | — |
| Site 99 | Miami | Florida | 33173 | — |
| Site 54 | Ocala | Florida | 34470 | — |
| Site 43 | Atlanta | Georgia | 30329 | — |
| Site 90 | Sandy Springs | Georgia | 30328 | — |
| Site 31 | Boise | Idaho | 83704 | — |
| Site 61 | Chicago | Illinois | 60610 | — |
| Site 53 | Clarksville | Indiana | 47129 | — |
| Site 15 | Indianapolis | Indiana | 46250 | — |
| Site 32 | New Albany | Indiana | 47150 | — |
| Site 55 | Plainfield | Indiana | 46168 | — |
| Site 27 | West Lafayette | Indiana | 47906 | — |
| Site 79 | Leawood | Kansas | 66211 | — |
| Site 52 | Louisville | Kentucky | 40241 | — |
| Site 41 | Baton Rouge | Louisiana | 70809 | — |
| Site 13 | Covington | Louisiana | 70433 | — |
| Site 12 | Metairie | Louisiana | 70006 | — |
| Site 75 | New Orleans | Louisiana | 70124 | — |
| Site 84 | Glenn Dale | Maryland | 20769 | — |
| Site 87 | Rockville | Maryland | 20850 | — |
| Site 22 | Brighton | Massachusetts | 02135 | — |
| Site 80 | Chestnut Hill | Massachusetts | 02467 | — |
| Site 59 | Quincy | Massachusetts | 02169 | — |
| Site 26 | Clarkston | Michigan | 48346 | — |
| Site 68 | Clinton Township | Michigan | 48038 | — |
| Site 83 | Southfield | Michigan | 48034 | — |
| Site 98 | Medina | Minnesota | 55340 | — |
| Site 56 | Minneapolis | Minnesota | 55455 | — |
| Site 6 | New Brighton | Minnesota | 55112 | — |
| Site 18 | Hackensack | New Jersey | 07601 | — |
| Site 37 | Kew Gardens | New York | 11415 | — |
| Site 97 | New York | New York | 10003 | — |
| Site 82 | Hickory | North Carolina | 28602 | — |
| Site 92 | Huntersville | North Carolina | 28078 | — |
| Site 39 | Boardman | Ohio | 44512 | — |
| Site 72 | Cincinnati | Ohio | 45236 | — |
| Site 11 | Columbus | Ohio | 43215 | — |
| Site 57 | Portland | Oregon | 97210 | — |
| Site 60 | Anderson | South Carolina | 29621 | — |
| Site 95 | Hermitage | Tennessee | 37076 | — |
| Site 9 | Knoxville | Tennessee | 37909 | — |
| Site 4 | Nashville | Tennessee | 37215 | — |
| Site 76 | Austin | Texas | 78746 | — |
| Site 74 | College Station | Texas | 77845 | — |
| Site 67 | Dallas | Texas | 75230 | — |
| Site 14 | Houston | Texas | 77056 | — |
| Site 88 | San Antonio | Texas | 78218 | — |
| Site 91 | Sugar Land | Texas | 77479 | — |
| Site 19 | South Jordan | Utah | 84095 | — |
| Site 29 | Forest | Virginia | 24551 | — |
| Site 63 | Norfolk | Virginia | 23502 | — |
| Site 85 | Norfolk | Virginia | 23502 | — |
| Site 33 | Burien | Washington | 98168 | — |
| Site 70 | Mill Creek | Washington | 98012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07146022, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07146022 live on ClinicalTrials.gov.